MiRNA-520b and miR-520e sensitize breast cancer cells to complement attack via directly targeting 3′UTR of CD46

Cancer Biology and Therapy

Volumn 10, Issue 3, 2010, Pages 232-241

  Cui, Wenjing ^a   Zhang, Yiwen ^a   Hu, Nan ^a   Shan, Changliang ^b   Zhang, Shuai ^b   Zhang, Weiying ^a   Zhang, Xiaodong ^b   Ye, Lihong ^a  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b NANKAI UNIVERSITY   (China)

Author keywords

Breast cancer; Complement attack; Complement dependent cytotoxicity; Complement regulatory protein; microRNA

Indexed keywords

BETA ACTIN; COMPLEMENT; COMPLEMENT COMPONENT C3B; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MEMBRANE COFACTOR PROTEIN; MICRORNA;

3' UNTRANSLATED REGION; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL IMMORTALIZATION; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; OPSONIZATION; SENSITIZATION;

EID: 77955488537     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.3.12277     Document Type: Article

References (33)

1. Jovanovic M, Hengartner MO. miRNAs and apoptosis: RNAs to die for. Oncogene 2006; 25:6176-87.
2. Lim LP, Glasner ME, Yekta S, Burge CB, Bartel DP. Vertebrate microRNA genes. Science (New York, NY) 2003; 299:1540.
3. Houbaviy HB, Murray MF, Sharp PA. Embryonic stem cell-specific MicroRNAs. Dev Cell 2003; 5:351-8.
4. Lagos-Quintana M, Rauhut R, Meyer J, Borkhardt A, Tuschl T. New microRNAs from mouse and human. RNA 2003; 9:175-9.
5. Tanzer A, Stadler PF. Molecular evolution of a microRNA cluster. J Mol Biol 2004; 339:327-35.
6. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6:857-66.
7. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, et al. RAS is regulated by the let-7 microRNA family. Cell 2005; 120:635-47.
8. Tran N, McLean T, Zhang X, Zhao CJ, Thomson JM, O'Brien C, Rose B. MicroRNA expression profiles in head and neck cancer cell lines. Biochem Biophys Res Commun 2007; 358:12-7.
9. Linghu H, Tsuda M, Makino Y, Sakai M, Watanabe T, Ichihara S, et al. Involvement of adaptor protein Crk in malignant feature of human ovarian cancer cell line MCAS. Oncogene 2006; 25:3547-56. (Pubitemid 43901676)
10. Jiang J, Lee EJ, Gusev Y, Schmittgen TD. Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res 2005; 33:5394-403.
11. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. Jama 2008; 299:425-36.
12. Bueno MJ, de Castro IP, Malumbres M. Control of cell proliferation pathways by microRNAs. Cell Cycle 2008; 7:3143-8.
13. Chen Y, Gorski DH. Regulation of angiogenesis through a microRNA (miR-130a) that downregulates antiangiogenic homeobox genes GAX and HOXA5. Blood 2008; 111:1217-26.
14. Lindsay MA. microRNAs and the immune response. Trends Immunol 2008; 29:343-51.
15. Li QJ, Chau J, Ebert PJ, Sylvester G, Min H, Liu G, et al. miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell 2007; 129:147-61.
16. Thai TH, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y, et al. Regulation of the germinal center response by microRNA-155. Science 2007; 316:604-8.
17. Gelderman KA, Blok VT, Fleuren GJ, Gorter A. The inhibitory effect of CD46, CD55 and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies. Lab Invest 2002; 82:483-93.
18. Liszewski MK, Farries TC, Lublin DM, Rooney IA, Atkinson JP. Control of the complement system. Adv Immunol 1996; 61:201-83.
19. Ross GD. Regulation of the adhesion versus cytotoxic functions of the Mac-1/CR3/alphaMbeta2-integrin glycoprotein. Crit Rev Immunol 2000; 20:197-222.
20. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001; 1:118-29. (Pubitemid 33741887)
21. Xia H, Qi Y, Ng SS, Chen X, Chen S, Fang M, et al. MicroRNA-15b regulates cell cycle progression by targeting cyclins in glioma cells. Biochem Biophys Res Commun 2009; 380:205-10.
22. Berezikov E, Guryev V, van de Belt J, Wienholds E, Plasterk RH, Cuppen E. Phylogenetic shadowing and computational identification of human microRNA genes. Cell 2005; 120:21-4. (Pubitemid 40094599)
23. Mishra PJ, Song B, Mishra PJ, Wang Y, Humeniuk R, Banerjee D, et al. MiR-24 tumor suppressor activity is regulated independent of p53 and through a target site polymorphism. PLoS One 2009; 4:8445.
24. Nakano H, Miyazawa T, Kinoshita K, Yamada Y, Yoshida T. Functional screening identifies a microRNA, miR-491 that induces apoptosis by targeting Bcl-X(L) in colorectal cancer cells. Int J Cancer 2009; [Epub ahead of print].
25. Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, Cordon-Cardo C, et al. miR-19 is a key oncogenic component of mir-17-92. Genes Dev 2009; 23:2839-49.
26. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and downregulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99:15524-9.
27. Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 2003; 40:109-23. (Pubitemid 36959821)
28. Rushmere NK, Knowlden JM, Gee JM, Harper ME, Robertson JF, Morgan BP, Nicholson RI. Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer. Int J Cancer 2004; 108:930-6.
29. Kojima A, Iwata K, Seya T, Matsumoto M, Ariga H, Atkinson JP, Nagasawa S. Membrane cofactor protein (CD46) protects cells predominantly from alternative complement pathway-mediated C3-fragment deposition and cytolysis. J Immunol 1993; 151:1519-27.
30. You J, Mi D, Zhou X, Qiao L, Zhang H, Zhang X, Ye L. A positive feedback between activated extracellularly regulated kinase and cyclooxygenase/ lipoxygenase maintains proliferation and migration of breast cancer cells. Endocrinology 2009; 150:1607-17.
31. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008; 3:1101-8.
32. Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001; 98:3383-9.
33. Shan C, Xu F, Zhang S, You J, You X, Qiu L, et al. Hepatitis B virus X protein promotes liver cell proliferation via a positive cascade loop involving arachidonic acid metabolism and p-ERK1/2. Cell Res 2010; 20:563-75.